Emily Gauer, PA
Physician Assistant · Terre Haute, INNPI 1891219820
Payments from drug & device makers
Across 141 payments — averaging $40.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insulet Corporation$3K
- Novo Nordisk$528
- AstraZeneca$479
- Sanofi-aventis U.S. LLC$344
- Tandem Diabetes Care, Inc.$247
- Sequel Med Tech, LLC$229
- plus $1K from 17 others
What the payments were for
- Speaking & faculty fees$2,30040%
- Food & beverage$3,39160%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insulet Corporation | 15 | $2,808 |
| Novo Nordisk | 44 | $528 |
| AstraZeneca | 12 | $479 |
| Sanofi-aventis U.S. LLC | 17 | $344 |
| Tandem Diabetes Care, Inc. | 3 | $247 |
| Sequel Med Tech, LLC | 3 | $229 |
| BETA Bionics, Inc. | 2 | $148 |
| Bayer | 5 | $140 |
| Medtronic | 3 | $122 |
| Lilly USA, LLC | 7 | $118 |
| AbbVie | 5 | $88 |
| Mannkind Corporation | 5 | $84 |
| Xeris Pharmaceuticals, Inc. | 4 | $73 |
| Cequr Corporation | 2 | $46 |
| Antares Pharma, Inc. | 3 | $41 |
| Amneal Pharmaceuticals LLC | 2 | $40 |
| Dexcom, Inc. | 2 | $38 |
| Abbott | 2 | $31 |
| Corcept Therapeutics | 1 | $29 |
| Averitas Pharma Inc. | 1 | $21 |
| Ascendis Pharma Endocrinology Inc | 1 | $14 |
| Merck | 1 | $12 |
| Currax Pharmaceuticals LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,691 in reported general payments places this provider in the 95th percentile of 1,955 physician assistant providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 805 | $943,730 |
| OzempicSemaglutide | 358 | $428,225 |
| FarxigaDapagliflozin Propanediol | 305 | $252,952 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 169 | $172,687 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 229 | $164,848 |
| JardianceEmpagliflozin | 101 | $98,627 |
| Tresiba Flextouch U-100Insulin Degludec | 141 | $92,209 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 44 | $78,527 |
| Tresiba Flextouch U-200Insulin Degludec | 70 | $74,445 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 62 | $70,190 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 70 | $67,147 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 86 | $54,204 |
| TrulicityDulaglutide | 44 | $52,332 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 30 | $45,275 |
| Humalog Kwikpen U-100Insulin Lispro | 124 | $43,103 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Lyumjev, Baqsimi, Humalog | $118 | $1,051,374982 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $528 | $471,607435 claims |
| AstraZenecaFarxiga | $479 | $252,952305 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $344 | $45,27530 claims |
| MerckJanuvia | $12 | $11,71217 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $40 | $11,434592 claims |
| AbbVieSynthroid | $88 | $8,748146 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,955 physician assistant providers in Indiana.
Other physician assistant in Terre Haute
- Lynnaire JastillanoTerre Haute$7K
- Kristen GumpfCarmel$142K
- Andrew NordIndianapolis$47K
- Qun Ming ZhangIndianapolis$28K
- Lauren HoweMunster$28K
- A FergusonFort Wayne$22K
- Jacquelyn BeemerFort Wayne$21K
- Lindsay YoderIndianapolis$21K
- Eryn GormanClinton$18K
- Audrey HewittBloomington$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.